Meeting News Coverage

Comparative trials of anti-VEGFs show no statistically significant differences, speaker says

NEW ORLEANS — Comparative studies such as CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS have shown no clinically significant differences between ranibizumab and bevacizumab, a speaker said here.

“There are no statistical differences between these small percentages. People keep trying to make it significant. It’s probably noise,” Daniel F. Martin, MD, chairman of the Cole Eye Institute, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Daniel F. Martin

Martin, chairman of the CATT, discussed the top findings from each of the comparative studies, citing that Lucentis (ranibizumab, Genentech) and Avastin (bevacizumab, Genentech) were found to be equivalent in terms of visual acuity; that the anatomical differences that occurred were small; and that there were no compelling and consistent data suggesting a systemic safety advantage for either drug.

“Very few of the differences between these drugs, whether they favor Lucentis or Avastin, are clinically significant,” Martin said. “I think we’re done with this question.”

Disclosure: Martin has no relevant financial disclosures.

NEW ORLEANS — Comparative studies such as CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS have shown no clinically significant differences between ranibizumab and bevacizumab, a speaker said here.

“There are no statistical differences between these small percentages. People keep trying to make it significant. It’s probably noise,” Daniel F. Martin, MD, chairman of the Cole Eye Institute, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Daniel F. Martin

Martin, chairman of the CATT, discussed the top findings from each of the comparative studies, citing that Lucentis (ranibizumab, Genentech) and Avastin (bevacizumab, Genentech) were found to be equivalent in terms of visual acuity; that the anatomical differences that occurred were small; and that there were no compelling and consistent data suggesting a systemic safety advantage for either drug.

“Very few of the differences between these drugs, whether they favor Lucentis or Avastin, are clinically significant,” Martin said. “I think we’re done with this question.”

Disclosure: Martin has no relevant financial disclosures.